Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma (original) (raw)

• Lenz G, Staudt LM . Aggressive lymphomas. N Engl J Med 2010; 362: 1417–1429.
  Article CAS Google Scholar
• DeVita Jr VT, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC . Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975; 1: 248–250.
  Article Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.
  Article CAS Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040–2045.
  Article CAS Google Scholar
• Friedberg JW . Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program 2011; 2011: 498–505.
  Article Google Scholar
• Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183–3190.
  Article CAS Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
  Article CAS Google Scholar
• Calado DP, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C et al. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 2010; 18: 580–589.
  Article CAS Google Scholar
• Crotty S, Johnston RJ, Schoenberger SP . Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol 2010; 11: 114–120.
  Article CAS Google Scholar
• Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K . Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003; 19: 607–620.
  Article CAS Google Scholar
• Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010; 18: 568–579.
  Article CAS Google Scholar
• Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM . Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006; 107: 4090–4100.
  Article CAS Google Scholar
• Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006; 203: 311–317.
  Article CAS Google Scholar
• Tate G, Hirayama-Ohashi Y, Kishimoto K, Mitsuya T . Novel BLIMP1/PRDM1 gene mutations in B-cell lymphoma. Cancer Genet Cytogenet 2007; 172: 151–153.
  Article CAS Google Scholar
• Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103–2113.
  Article CAS Google Scholar
• Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 2014; 27: 958–971.
  Article CAS Google Scholar
• Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L et al. Clinical implications of phosphorylated STAT3 expression in de novo diffuse large B-cell lymphoma. Clin Cancer Res 2014; 20: 5113–5123.
  Article CAS Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121: 4021–4031.
  Article CAS Google Scholar
• Xu-Monette ZY, Moller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC et al. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 122: 2630–2640.
  Article CAS Google Scholar
• Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL Rituximab-CHOP Consortium Program Study. Haematologica 2013; 98: 255–263.
  Article CAS Google Scholar
• Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012; 120: 3986–3996.
  Article CAS Google Scholar
• Dybkaer K, Bogsted M, Falgreen S, Bodker JS, Kjeldsen MK, Schmitz A et al. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol 2015; 33: 1379–1388.
  Article Google Scholar
• Lin R, Chen L, Chen G, Hu C, Jiang S, Sevilla J et al. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Invest 2014; 124: 5352–5367.
  Article Google Scholar
• White CA, Pone EJ, Lam T, Tat C, Hayama KL, Li G et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol 2014; 193: 5933–5950.
  Article CAS Google Scholar
• Liang L, Nong L, Zhang S, Zhao J, Ti H, Dong Y et al. The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type. J Exp Clin Cancer Res 2014; 33: 7.
  Article Google Scholar
• Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC et al. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia 2011; 25: 145–152.
  Article CAS Google Scholar
• Nie K, Zhang T, Allawi H, Gomez M, Liu Y, Chadburn A et al. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol 2010; 177: 1470–1479.
  Article CAS Google Scholar
• Klein U, Dalla-Favera R . Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008; 8: 22–33.
  Article CAS Google Scholar
• Calfon M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 2002; 415: 92–96.
  Article CAS Google Scholar
• Namba T, Chu K, Kodama R, Byun S, Yoon KW, Hiraki M et al. Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1alpha/XBP1 pathway. Oncotarget 2015; 6: 19990–20001.
  Article Google Scholar
• Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007; 12: 280–292.
  Article CAS Google Scholar
• Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008; 111: 1515–1523.
  Article CAS Google Scholar
• Gyory I, Fejer G, Ghosh N, Seto E, Wright KL . Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol 2003; 170: 3125–3133.
  Article Google Scholar
• Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K . Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol 2000; 20: 2592–2603.
  Article CAS Google Scholar
• Liu H, Ippolito GC, Wall JK, Niu T, Probst L, Lee BS et al. Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. Mol Cancer 2006; 5: 18.
  Article Google Scholar
• Gustafson WC, Weiss WA . Myc proteins as therapeutic targets. Oncogene 2010; 29: 1249–1259.
  Article CAS Google Scholar
• Johnson K, Shapiro-Shelef M, Tunyaplin C, Calame K . Regulatory events in early and late B-cell differentiation. Mol Immunol 2005; 42: 749–761.
  Article CAS Google Scholar
• Heise N, De Silva NS, Silva K, Carette A, Simonetti G, Pasparakis M et al. Germinal center B cell maintenance and differentiation are controlled by distinct NF-kappaB transcription factor subunits. J Exp Med 2014; 211: 2103–2118.
  Article CAS Google Scholar
• Liu YY, Leboeuf C, Shi JY, Li JM, Wang L, Shen Y et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood 2007; 110: 339–344.
  Article CAS Google Scholar
• Kusam S, Vasanwala FH, Dent AL . Transcriptional repressor BCL-6 immortalizes germinal center-like B cells in the absence of p53 function. Oncogene 2004; 23: 839–844.
  Article CAS Google Scholar
• Martins G, Calame K . Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 2008; 26: 133–169.
  Article CAS Google Scholar
• Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM . A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991–9996.
  Article CAS Google Scholar
• Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, Maestre L, Sanchez-Verde L, Roncador G et al. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010; 95: 1342–1349.
  Article Google Scholar
• Garcia JF, Roncador G, Garcia JF, Sanz AI, Maestre L, Lucas E et al. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica 2006; 91: 467–474.
  CAS PubMed Google Scholar
• Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17: 51–62.
  Article CAS Google Scholar
• Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88–92.
  Article CAS Google Scholar